Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Albigès et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d91684d8690e49a78358b7 — DOI: https://doi.org/10.1136/esmoopen-2020-001079

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial· 2019 · 775 citations
2. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial· 2020 · 224 citations
3. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study· 2009 · 2,119 citations
4. Meta-analysis in clinical trials· 1986 · 39,080 citations
5. The promise of Immuno-oncology: implications for defining the value of cancer treatment· 2019 · 114 citations